There are probably 70,000 more diabetic patients in this country using insulin today than there were a year ago, and I attribute this increase chiefly to the discovery of protamine insulin by Dr. Hagedorn of Copenhagen. His discovery stimulated the use of insulin and insulin it is which has lessened coma and made it inexcusable, has raised the life expectancy of 10 year old diabetic children from two years to 31.7 years, and has trebled the duration of diabetes for all diabetic patients and even deferred premature arteriosclerosis by two years or more. The simplicity and convenience of administering insulin once a day have appealed to the diabetic public, and is it any wonder that they have turned to it or that I should feel still more strongly now than a year and a half ago that, in recognition of this extension of the use of insulin—an indirect benefit—and of
JOSLIN EP. PROTAMINE INSULIN: CLINICAL LECTURE AT ATLANTIC CITY SESSION. JAMA. 1937;109(7):497–503. doi:https://doi.org/10.1001/jama.1937.92780330003010
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: